As such, DYRK2 may offer value as a prognostic biomarker in this cancer type, with CRC patients exhibiting lower levels of DYRK2 expression potentially requiring closer monitoring than patients expressing higher levels of this gene. The gene discussed is DYRK2; the disease is cancer.